Monoclonal antibodies (MAb) 3F11 and 06B4 recognize epitopes that are conserved on gonococcal lipooligosaccharides (LOS), present on some meningococcal LOS, and conserved on human erythrocytes. LOS of some group B and C prototype meningococcal LOS strains (LOS serotypes Ll to L8) treated with neuraminidase showed increased expression of the 3F11 and 06B4 MAb-defined epitopes. Neuraminidasetreated LOS separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and silver stained showed a shift in migration from a component with a mass of approximately 4.8 kDa to a component with a mass of between 4.5 and 4.6 kDa. The same strains grown in medium with excess CMP-N-acetylneuraminic acid had LOS that shifted in migration to a slightly higher component (mass, approximately 4.8 kDa). Chemical analysis of the neuraminidase-digested products from one LOS indicated it contained approximately 1.5% sialic acid. Covalent linkage between sialic acid and the LOS was confirmed by analysis of de-O-acylated and dephosphorylated LOS by liquid secondary ion mass spectrometry. These studies show that some meningococci contain sialic acid in their LOS, that the sialic acid is cleaved and lost in conventional acetic acid hydrolysis, and that the sialic acid alters the expression of MAb-defined epitopes. Recent studies have shown that when gonococci are grown in the presence of CMP-N-acetylneuraminic acid (CMP-NANA), sialic acid is incorporated into the LOS component of 4.5 kDa that binds MAbs 3F11 and 06B4 (36, 44). The sialylated component no longer binds the MAbs (4, 36). Treatment of the LOS with neuraminidase restores these epitopes, both on organisms grown in vitro (36) and on organisms in vivo in urethral exudates (4). Although the 3F11 and 06B4 epitopes are of similar specificity and are both expressed on gonococcal LOS (37), the 06B4 epitope is expressed much better than is the 3F11 epitope on meningococcal LOS of group B and C strains (30, 35 Bacterial strains. The prototype group B and C meningococcal LOS strains (38, 62) have been described previously.
The surface glycolipids (lipooligosaccharides [LOS]) of Neisseria gonorrhoeae and Neisseria meninigitidis are composed of multiple components that are antigenically and chemically distinct (21, 37) . Many gonococcal and meningococcal strains contain LOS that bind monoclonal antibodies (MAbs) 3F11 and 06B4, usually to a 4.5-kDa LOS component. The shared epitopes defined by MAbs 3F11 and 06B4 (35) are conserved on gonococcal LOS (3, 4, 37) but variably expressed on LOS of meningococci (31, 35) , Neisseria lactamica (30) , and Haemophilus ducreyi (9) . These MAbs also have been used to show that certain LOS components are immunochemically similar to molecules present in human erythrocytes and in other human cells (35) . MAbs 3F11 and 06B4 bind to mammalian glycosphingolipids that have terminal GalP1-*4GlcNAc structures (35) .
Recent studies have shown that when gonococci are grown in the presence of CMP-N-acetylneuraminic acid (CMP-NANA), sialic acid is incorporated into the LOS component of 4.5 kDa that binds MAbs 3F11 and 06B4 (36, 44) . The sialylated component no longer binds the MAbs (4, 36) . Treatment of the LOS with neuraminidase restores these epitopes, both on organisms grown in vitro (36) and on organisms in vivo in urethral exudates (4) . Although the 3F11 and 06B4 epitopes are of similar specificity and are both expressed on gonococcal LOS (37) , the 06B4 epitope is expressed much better than is the 3F11 epitope on meningococcal LOS of group B and C strains (30, 35) . Because of these results, we wondered whether the difference in the expression of the two MAb-defined epitopes on meningococci could be due to sialylation of their LOS. In the present 2824 MANDRELL ET AL. have been described previously. MAb 2-2-B, specific for meningococcal group B polysaccharide (39) , was the kind gift of Wendell Zollinger. LOS. The LOS used for solid-phase radioimmunoassay (SPRIA) and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) were purified as described previously (49, 56) . We also purified larger amounts of a single LOS for chemical analysis. In brief, meningococcal group B strain 6275 was grown in 11 liters of liquid 4x Frantz medium (34) in a fermentor (Lab-line Bioengineering, Melrose Park, Ill.). Acetone-dried organisms were added to 50 mM phosphate-buffered saline (PBS)-5 mM EDTA (pH 7.4) to make a 10% solution. This mixture was blended to make a suspension, and lysozyme (grade I; Sigma) was added to a 0.2% final concentration. This mixture was stirred at 4°C for 2 h and then at 37°C for 20 min. MgCl2 was added to a 20 mM final concentration, and the suspension was mixed. DNase and RNase (Sigma) were each added to a final concentration of 3 ,ug/ml, and the suspension was incubated and stirred at 37°C for 15 min. LOS was extracted from this solution by the hot phenol water procedure of Westphal and Jann (56) . The final product had <2% nucleic acid and <2% protein, as assessed by the ratio of the optical densities of the sample at wavelengths of 280 and 260 nm. MAb 2-2-B (specific for the sialic acid-containing meningococcal group B polysaccharide) (39) was tested in a SPRIA inhibition assay with strain 6275 LOS and purified group B polysaccharide as inhibitors of the anti-group B polysaccharide MAb (61) . The results indicated that antigenic group B polysaccharide contamination of the LOS was <0.3%.
OMCs. Outer membrane complexes (OMCs) were prepared from meningococci as described previously (63) .
SDS-PAGE and immunoblotting. LOS samples were separated through polyacrylamide slab gels by the method of Laemmli (32) . Immunoblotting (37) and silver staining (54) were done as described previously. (50) .
SPRIA. SPRIA was performed as described previously (37, 60) . Stock solutions of LOS or OMCs were diluted in Dulbecco PBS modified to contain 50 mM MgCl2. A 25- ,ug/ml solution of LOS or OMC (based on protein concentration) was used to sensitize polyvinyl microtiter plate wells. In some assays, plates were sensitized with whole organisms as described previously (1). 40 ,u1 of methanol, and 1 p.l of acetic acid. The solution was vortexed, heated at 80°C for 30 min, and dried under N2. The OS samples derivatized with 4-BPH were purified on a reverse-phase C18 column (Vydac; 25 by 4.6 cm) with UV detection at 335 nm. A linear gradient of 0 to 55% acetonitrile-water (1 ml/min) containing 0.05% trifluoroacetic acid was used for elution of the OS.
LSIMS. For liquid secondary ion mass spectrometry (LSIMS) analysis, the OS samples derivatized with 4-BPH were dissolved in water, and the de-O-acylated LOS samples were dissolved in methanol-water (1:1). Analysis was performed with a Kratos MSSOS mass spectrometer with a cesium ion source (13, 18) . Approximately 1 of glycerolthioglycerol (1:1) was applied to the stainless steel probe tip, and portions of the dissolved samples were added. The primary ion (Cs') ion beam energy was 10 keV, and the accelerating voltage of the secondary ions was 8 kV. The spectra were acquired in the negative-ion mode.
RESULTS
Binding of MAbs 3F11 and 06B4 to neuraminidase-treated LOS of serotype Li to L8 prototype strains. Table 1 shows the binding of MAbs 3F11 and 06B4 to meningococcal Li to L8 prototype strains before and after the strains were treated with neuraminidase. The LOS of L2, L3, and L4 showed a marked increase in the binding of MAb 3F11 after treatment with neuraminidase (<1% of maximum binding before neuraminidase as compared with 53 to 100% of maximum binding after neuraminidase). The L5, L7, and L8 LOS showed small or moderate increases in the binding of MAb 3F11 after enzyme treatment. MAb 06B4 also showed minimal binding to the L2 and L3 LOS but bound well to the L4 LOS; a marked increase in binding occurred after treatment of these LOS with neuraminidase. In numerous studies with native LOS (non-enzyme treated), we have noted that the L2, L3, and L4 LOS often are negative for binding of MAb 3F11 but vary in their binding of MAb 06B4 (data not shown). Nitrocellulose-immobilized LOS modified by neuraminidase. Meningococcal LOS that showed a significant increase in the expression of the MAb 3F11-defined epitope after neuraminidase treatment (L2, L3, and L4; Table 1 ) were separated by SDS-PAGE, transferred to nitrocellulose, treated with neuraminidase, and tested with MAb 3F11. For some of the strains, an OMC antigen was also tested to represent a more native form of the antigen (Fig. 1) (Fig. 1C,  lanes 1 to 3 and 6 to 8 ). The smearing in the enzyme-treated samples could have been due to increased epitope expression on LOS dimer or trimer aggregates (Fig. 1A and B, lane  8) and/or the presence of other forms of sialylated LOS that do not resolve into defined bands and do not stain well with silver.
Shift in the LOS component(s) after neuraminidase treatment. In SDS-PAGE, a silver-stained band of neuraminidase-treated and SDS-PAGE-separated LOS of strains 35E and 89I migrated at a slightly lower mass (Fig. 2, lanes 2 and  4) than did that of non-neuraminidase-treated LOS (Fig. 2,  lanes 1 and 3) . These results indicated that neuraminidase cleaved the high-mass component (Fig. 2, top arrow) of these LOS and that the resulting product migrated to an identical, or very similar, mass as did the lower-mass component (Fig. 2, bottom arrow) .
Shift in the migration of LOS from organisms grown with CMP-NANA. Strains 35E, 6275, and 891 were grown in the absence and presence of CMP-NANA, and the organisms were tested for expression of the MAb 3F11-defined epitope (Fig. 3) Figure   4 shows the silver stain (panel A) and autoradiograph (panel B) of LOS from these organisms. Strain 6275 incorporated radioactive NANA in its LOS (panel B), but strain 126E did not. In addition, there was no obvious difference in the LOS profiles of organisms grown with and without CMP-NANA (panel A).
IEM. We tested neuraminidase-treated meningococci by IEM to determine whether the exposed 3F11 epitope was surface expressed. Figure 5 shows LSIMS analysis of partially deacylated strain 6275 LOS. Strain 6275 LOS that was sequentially de-O-acylated and dephosphorylated was analyzed by LSIMS to confirm the presence of a covalent linkage between the sialic acid and the LOS. The peak at m/z 2508 is consistent with the (M -H)-ion for de-O-acylated lipid A attached to an OS of the composition Hex3HexNAc2Hep2KDO2 (Fig. 6A) . However, the peak at m/z 2799 (M -H)-has an additional 291 Da and corresponds to the addition of sialic acid (N-acetylneuraminic acid). The molecular ion at m/z 871 corresponds to a monophosphorylated lipid A moiety that was not completely cleaved by dephosphorylation, whereas the (M -H)-ion at mlz 2799 contains no phosphate moieties. The mass of the peak at m/z 1231 (Y3) is consistent with a reducing terminal fragment containing two KDO moieties plus the nonphosphorylated lipid A moiety (791 Da). The peak at mlz 1011 (Y3 minus KDO) corresponds to a single KDO moiety plus the nonphosphorylated lipid A moiety. The difference between the molecular ions at mlz 871 and m/z 1273 could be explained by the addition of KDO and one lauric acid. Several smaller peaks at low masses (mlz 977, 1169, 1389) could not be readily explained in terms of the structures shown and may have been the result of heterogeneity in the LOS or artifacts of the chemical modifications (18) . At this stage in our structural analysis of strain 6275 LOS, we do not know whether the two KDOs are branched or linked in series. LSIMS analysis of a mutant gonococcal LOS of strain FA5100 suggests that one of the two KDOs is terminal and nonreducing (47) and, therefore, is consistent with the branched structure shown in Fig. 6A .
LSIMS analysis of the acid-hydrolyzed OS moiety after conversion to its 4-BPH derivative is shown in Fig. 6B to Hex3HexNAc2Hep2KDO-BPH. The (M -H)-ion at mlz 1701, which is 42 Da larger than the (M -H)-ion at m/z 1659, likely corresponds to the addition of an 0-acetate moiety that was partially removed by dephosphorylation of the OS. The peak at mlz 998 is an X-type ion formed by ring cleavage of the heptose attached to the KDO moiety. The peak at mlz 1335, however, differs from the molecular ion peak at m/z 1659 by the loss of two hexose residues. Since no simple cleavage could result in the loss of two hexoses from the structure shown in Fig. 6B , we speculate that this ion may originate from an additional OS structure present in this preparation. DISCUSSION We have shown that some strains of N. meningitidis have sialic acid in their LOS and that this sialic acid alters the expression of the epitopes defined by MAb 3F11 and, to a lesser extent, MAb 06B4. The presence of sialic acid in some meningococcal LOS is indicated by the following observations. (i) LOS epitopes are exposed by neuraminidase (Table  1 and Fig. 1). (ii) Neuraminidase-treated LOS runs faster in SDS-PAGE than does untreated LOS (Fig. 2) . (iii) LOS from organisms grown with CMP-NANA runs slower in SDS-PAGE than does LOS from untreated organisms (Fig. 3) . (iv) Organisms grown with CMP-[14C]NANA incorporate radioactivity only in their LOS (Fig. 4) . (v) The product released from neuraminidase-treated LOS is as sialic acid. (vi) LSIMS analysis of partially deacylated LOS reveals a fragmentation pattern characteristic of a sialylated molecule (Fig. 6) .
Seven of eight group B and C prototype LOS strains (Table 1) have an LOS component in the range of 4.5 kDa (L2 to L8); except for strain M992 (L6), the LOS of these strains showed at least a partial increase in the binding of MAb 3F11 or 06B4 after treatment with neuraminidase. These results indicate that the 4.5-kDa component is strongly associated with 3F11 and 06B4 epitope expression. The MAb 3F11 binding-negative, MAb 06B4 binding-positive epitope expression on the L4 LOS before treatment with neuraminidase was consistent with our previous results for meningococcal LOS (30, 35) . However, the lower expression of the 3F11 (on L5 and L7 LOS) and 06B4 (on L2 and L3 LOS) epitopes in this study than in the previous studies (30, 35) indicated that epitope expression could vary. We have noted differences in the expression of these two epitopes depending on whether whole organisms, OMCs, or purified LOS are used as antigens (data not shown), possibly reflecting the labile nature of the putatively sialylated epitopes during antigen preparation. From the results of this study and other studies (30, 35) , we predict that many group B and C strains possess the potential to express the 3F11 and 06B4 epitopes but that, on some strains, the epitopes are covered by sialic acid and that, on other strains, the unsialylated epitopes are expressed only at very low levels (Table 1) .
Careful inspection of the silver stain profiles of the preneuraminidase-treated LOS in Fig. 2 (Fig. 3) associated with decreased expression of the lowermass component (approximately 4.5 kDa) and of the 3F11 and 06B4 epitopes. As noted, these results differ from the SPRIA results for some endogenously sialylated LOS, which showed an absence of 3F11 epitope expression with strong 06B4 epitope expression (Table 1) (30, 35) . One explanation for this difference could be that since only endogenous (organism-synthesized) CMP-NANA is available in nonsupplemented medium, increased levels of exogenously sialylated LOS (Fig. 3 , CMP-NANA+) as compared with endogenously sialylated LOS (Fig. 3 , CMP-NANA-) may reflect a disruption or alteration in the regulation of sialylation of the capsule and/or LOS. The complexity of this regulation is reflected by the multiple enzymes required for the synthesis of the sialic acid capsule of group B meningococci (a2-*8-linked sialic acid homopolymer). For capsule synthesis, group B meningococci have an N-acetylneuraminic acidcondensing enzyme, a CMP-NANA synthetase, a CMP-NANA hydrolase, and a chain-elongating sialyltransferase (40) . It has been hypothesized that the CMP-NANA hydrolase regulates the capsular sialyltransferase and that the CMP-NANA hydrolase is regulated by the concentration of free CMP (40) . Our studies suggest that group B and C organisms also have an LOS-specific sialyltransferase. Therefore, it will be important to determine whether the previously described sialic acid-associated enzyme activities and their regulation are related to the LOS-specific sialyltransferase activity.
Although the presence of sialic acid in meningococcal glycolipids has been reported by numerous investigators (19, 23, 27, 28, 41) , it should be noted that the results of these and other studies (10, 20, 42, 45, 46, 49, 51, 58) were derived from material cleaved under acidic conditions that could degrade possible constituents of LOS (e.g., sialic acid, fucose, and phosphate) (Fig. 6B) . Therefore, alternative methods of chemical analysis may be needed to obtain a more complete picture of the native LOS structure. Two alternatives that we used for the studies reported here and that may prove useful for the chemical analysis of other neisserial LOS were anion-exchange chromatography of neuraminidase-treated LOS and mass spectrometric analysis of partially intact LOS.
Analysis of a neuraminidase-treated LOS by strong anionexchange chromatography indicated that strain 6275 LOS was composed of approximately 1.5% sialic acid. The approximately 300-to 400-Da difference in the migration of the LOS after neuraminidase treatment and/or because of growth in CMP-NANA ( Fig. 2 and 3 strain used as the source of the LOS (group B strain 6275) also produced a sialic acid capsule, it was important to confirm that the neuraminidase-sensitive sialic acid in the LOS preparation was covalently bound to the LOS. LSIMS of partially deacylated LOS allowed identification of the peaks for the molecular ion [(M -H)-ion of m/z 2799], for a lower-mass ion (m/z 2508) corresponding to the release of sialic acid, and for a third ion (m/z 2346) corresponding to the release of sialic acid and hexose (Fig. 6A) . Although mass spectrometric analysis of intact (nonhydrolyzed and nonderivatized) LOS has been relatively unsuccessful, partial deacylation of LOS by hydrazinolysis has been used for nuclear magnetic resonance analysis (24) . Hydrazinolysis of LOS releases 0-linked fatty acids from the lipid A moiety (24) . For strain 6275 LOS, this treatment resulted in a decrease in the hydrophobicity of the LOS as compared with that of the untreated LOS (data not shown) and an increase in the sputtering efficiency of the molecular ion and other fragments (Fig. 6A) .
If it is assumed that the LOS of strains 6275 and 891 are composed of a single component with a mass of 4.8 kDa (4.5-kDa component plus approximately 0.3 kDa for N-acetylneuraminic acid) and that each LOS molecule has one sialic acid, then the sialic acid in 1 mg of LOS would be approximately 64 jig (6.4% ). This value is somewhat higher than the approximately 4% sialic acid that we measured for strain 6275 LOS by a resorcinol assay (52) (data not shown) and the 1.5% sialic acid that we measured by anion-exchange chromatography. This lower experimental value could reflect heterogeneous sialylation of LOS (Fig. 2) , incomplete sialylation of individual LOS components, and/or incomplete neuraminidase cleavage of sialic acid from LOS.
More complete chemical studies will be required to characterize the exact structure of the sialylated LOS. Jennings and co-workers used nuclear magnetic resonance to study acid-released OS of LOS and reported that the terminal tetrasaccharide of the nonreducing end of the LOS of an L2 strain (17, 26) , an L3, 7, 9 strain (29) , and an L5 strain (42) is composed of lacto-N-neotetraose (Gal1-4GlcNAcP1-, 3GalP1--4Glc). Also consistent with this structure are a common structure deduced by fast-atom-bombardment spectrometry analysis of acid-released OS of meningococcal strains 891 (L4) and M981 (L5) (10) and part of the preliminary structure described for the L3 LOS in this study (Fig. 6 : Hex-HexNAc-Hex-Hex-). Also, the presence of an 0-acetate moiety on the nonreducing terminal HexNAc of strain 6275 LOS (Fig. 6B ) is in agreement with the results of previous studies of N. meningitidis (10, 11) and N. gonorrhoeae (47) LOS.
The presence of lacto-N-neotetraose in neisserial LOS is notable because it is also present in paragloboside, a glycosphingolipid precursor of the major human blood group antigens (22) and of some sialylated glycosphingolipids (gangliosides) in human cells (16, 33) . However, in preliminary studies done to determine the nature of the sialic acid linkage on LOS, we found that MAbs specific for sialylated carbohydrates of mammalian glycoconjugates, such as sialic acid, bound ot2-*3 or a2-+6 to lactosamine (GalP1-*4GlcNAc) or a2--3 to GalP1->3GalNAc, did not bind to sialylated LOS of either meningococci (data not shown) or gonococci (36) . These results suggested that the sialylated LOS have a structure different from those recognized by these MAbs or that the LOS have the same structure but not in a recognizable conformation (59) .
What might be the functions of sialylated LOS for meningococci in vivo? One function could be to increase the serum resistance of the strains. Although it has been shown that gonococci grown in the presence of CMP-NANA become more resistant to human serum (43, 44) , in contrast, recent studies have shown no effect of CMP-NANA on the serum resistance of group A, B, Y, and Z and noncapsulated meningococci (14) . This difference may be related to the fact that group B, C, W, and Y meningococci synthesize CMP-NANA, but gonococci do not (7, 15, 55) . In light of the results that we have described, it would be interesting to know whether the meningococcal strains that were tested in the serum resistance studies had sialylated LOS. Although serum-sensitive meningococcal strains having "completely" sialylated LOS would suggest a limited role for sialylation in meningococcal serum sensitivity, it is possible that sialylated neisserial LOS are involved in mechanisms of pathogenesis other than serum resistance. For example, gonococci present in male urethral exudates also appear to have sialylated LOS (4), possibly reflecting the availability of sufficient CMP-NANA in the environment of the urethral epithelium and associated neutrophils and at this phase of the infectious process, in contrast to the absence of free CMP-NANA in human plasma (8) . Similarly, it will be important to determine whether meningococcal LOS also are sialylated in vivo and, if so, where the sialylated LOS exist (nasopharynx, blood, cerebrospinal fluid). Other biological functions of sialic acid that are relevant to concepts of meningococcal pathogenesis and host and tissue specificity are lack of recognition by mucosal antibody, complement, phagocytes (48) , and terminal galactose-specific lectins (6) and, conversely, recognition by sialic acid-specific lectins (2) . Whether the differences observed for in vitro LOS expression accurately reflect any in vivo mechanisms of meningococcal pathogenesis will be an area for future studies.
